Califf Says Opioid Labeling Changes, Withdrawals Still Possible
Executive Summary
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.
You may also be interested in...
OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule
Financial model is not adequate right now, FDA Commissioner Robert Califf says, so the agency may make regulatory changes to motivate sponsors.
OTC Naloxone May Get Another Push From US FDA As Agency Prepares Novel Switch Proposed Rule
Financial model isn't adequate currently, FDA Commissioner Robert Califf says, and agency may make regulatory changes to motivate sponsors.
US FDA Considering Opioid Mail-Back Envelope Mandate, But Industry Has Heard This Before
Sponsors would be required to furnish patients with pre-paid envelopes to mail back unused opioid medications for disposal. Comments on FDA's proposal could follow industry concerns about burden on health care system voiced when the idea was floated in 2018.